IDEXX Laboratories vs QuidelOrtho
IDXX and QDEL side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IDXX and QDEL compare
IDEXX Laboratories is the larger company, worth 48 times as much as QuidelOrtho ($43.4B against $909M).
IDEXX Laboratories grew revenue faster over the last twelve months (12.8% versus −2.5% for QuidelOrtho).
IDEXX Laboratories keeps more of each dollar of sales as profit, with a net margin of 25.0% compared with −39.2% at QuidelOrtho.
IDEXX Laboratories scores higher on the StockData Score (19 against 6 for QuidelOrtho), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IDXX | QDEL |
|---|---|---|
| Size and price | ||
| Market cap | $43.4B | $909M |
| Share price | $551.21 | $13.25 |
| Change, 1 year | −12.2% | −52.6% |
| Change, 5 years | −13.5% | −89.1% |
| Beta (5Y) | 1.22 | 0.85 |
| Employees | 11K | 6,500 |
| StockData Score | ||
| Total score | 19 (better) | 6 |
| Valuation score | 2 | 3 (better) |
| Growth score | 5 (better) | 0 |
| Performance score | 6 (better) | 2 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 38.8× | – |
| P/S | 9.5× | 0.3× (better) |
| P/B | 26.9× | 0.5× (better) |
| EV/EBITDA | 27.1× | – |
| P/FCF | 34.6× | – |
| PEG | 2.19 | – |
| FCF yield | 2.9% (better) | −23.2% |
| Fair value | $507.90 | $84.25 |
| Margin of safety | −8.5% | 84.3% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.8% (better) | −2.5% |
| Revenue growth, 5Y average | 9.7% | 10.4% (better) |
| Net income growth (TTM) | 15.6% | – |
| EPS growth (TTM) | 18.4% | – |
| EPS growth, 5Y average | 14.3% | – |
| Profitability | ||
| Gross margin | 62.4% (better) | 44.6% |
| Operating margin | 32.0% (better) | −30.8% |
| Net margin | 25.0% (better) | −39.2% |
| FCF margin | 27.5% (better) | −7.9% |
| Return on equity | 74.2% (better) | −45.9% |
| Return on invested capital | 63.3% (better) | −13.3% |
| Financial health | ||
| Debt / equity | 0.28 (better) | 1.63 |
| Net debt / EBITDA | 0.16 | – |
| Interest coverage | 38.6× (better) | −4.1× |
| Current ratio | 1.17 | 1.39 (better) |
| Altman Z-score | 19.89 (better) | −0.08 |
| Piotroski F-score | 8 (better) | 6 |
| Dividends and buybacks | ||
| Buyback yield | 2.7% (better) | −0.57% |
| Shareholder yield | 2.7% (better) | −0.57% |
| Ownership | ||
| Held by institutions | 94.5% | 121% |
| Held by insiders | 0.30% | 43.4% |
| Insider net buying, 12 months | −$37.7M | $1.2M (better) |
| Superinvestors holding | 3 | – |
| Short interest, % of float | 2.5% | 38.5% |
Go deeper
- IDXX stock overview
- IDXX income statement
- IDXX valuation and score
- QDEL stock overview
- QDEL income statement
- QDEL valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.